积极信号！大量资金涌入

Core Viewpoint - The innovative drug sector has experienced a strong rise in the first three quarters of the year, but has recently entered a phase of volatility, prompting a focus on selective stock picking and quality companies for future investment opportunities [1][3][8]. Group 1: Market Performance - The innovative drug sector has shown impressive performance this year, with several thematic funds doubling in value, but has faced an average decline of about 10% since the beginning of the fourth quarter [3]. - Despite the recent downturn, significant capital inflow into innovative drug ETFs has been observed, with a net subscription exceeding 19 billion yuan since the fourth quarter began [4]. Group 2: Fund Inflows - Major ETFs in the innovative drug sector have seen substantial net subscriptions, including 3.327 billion yuan for the GF Hong Kong Innovative Drug ETF and over 3 billion yuan for the Huatai-PineBridge Hong Kong Innovative Drug ETF [4]. - The scale of several innovative drug ETFs has significantly increased this year, with the GF Hong Kong Innovative Drug ETF growing from 7.875 billion yuan at the end of last year to 25.276 billion yuan as of November 28 [4]. Group 3: Future Outlook - The innovative drug sector is expected to undergo differentiation, with a need for selective stock picking as the era of broad-based gains may be over [8]. - The future success of companies in the innovative drug sector will depend on their ability to translate scientific innovations into commercial success, with a more rigorous market scrutiny on clinical data and financial performance [8][9].